---
title: The Effect of Nandrolone Decanoate and Leucine on Muscle Loss
nct_id: NCT02376309
overall_status: COMPLETED
phase: NA
sponsor: Maastricht University Medical Center
study_type: INTERVENTIONAL
primary_condition: Muscle Atrophy
countries: Netherlands
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02376309.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02376309"
ct_last_update_post_date: 2017-08-29
last_seen_at: "2026-05-12T07:24:20.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# The Effect of Nandrolone Decanoate and Leucine on Muscle Loss

**Official Title:** The Effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss

**NCT ID:** [NCT02376309](https://clinicaltrials.gov/study/NCT02376309)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Maastricht University Medical Center
- **Conditions:** Muscle Atrophy
- **Start Date:** 2015-08
- **Completion Date:** 2017-08
- **CT.gov Last Update:** 2017-08-29

## Brief Summary

A decrease in muscle mass can have a profound impact on quality of life, as it can lead to decreased strength, insulin resistance, lower basal metabolic rate and obesity. With this study we investigate whether ingesting leucine or getting a ND injection will reduce the loss of muscle mass and strength.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 35 Years
- **Sex:** MALE
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Healthy men 18-35 years
* BMI between 18.5 and 30 kg/m2

Exclusion Criteria:

\- (Family) history of thromboembolic events

* Smoking
* Recent surgery (within 6 months prior to the study)
* Performing progressive resistance training more than three times per week in the past year
* Any back/leg/knee/shoulder complaints which may interfere with the use of crutches
* Current systemic use of corticosteroids, anabolic steroids, growth hormone, testosterone, nandrolone, protein supplements, immunosuppressants or insulin, blood sugar decreasing medication or EPO
* All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis)
* Use of anti-coagulants
* Pre-existing renal disease or those with a potential risk for renal dysfunction (diabetes, hypertension, reduced glomerular filtration rate)
* Liver disease
* Heart failure
* Migraine
* Allergy to nuts or soy
* High blood pressure (\>140 mmHg systolic and \>90 mmHg diastolic) In case of doubt, in- or exclusion of subject will be discussed with responsible physician or principal investigator.
```

## Arms

- **Leu during inactivity** (EXPERIMENTAL) — Leucine supplements
- **ND during inactivity** (EXPERIMENTAL) — Nandrolone injection

## Interventions

- **Inactivity** (BEHAVIORAL) — Inactivity
- **ND** (DRUG) — 1 nandrolone decanoate injection
- **Leu** (DIETARY_SUPPLEMENT) — Leucine supplements

## Primary Outcomes

- **CSA Quadriceps (CT scan)** _(time frame: 7 days)_ — CT scan

## Secondary Outcomes

- **Muscle strength as measured by 1RM test** _(time frame: 7 days)_
- **Muscle fiber type and CSA as measured by histochemistry from the muscle biopsy** _(time frame: 7 days)_

## Locations (1)

- Maastricht University Medical Centre+, Maastricht, Limburg, Netherlands

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.maastricht university medical centre+|maastricht|limburg|netherlands` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02376309.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02376309*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*